Insider Trading April 15, 2026 08:47 PM

Alignment Healthcare President Disposes $626K in Stock Amid Near-Term Catalysts

Dawn Christine Maroney reduces holdings by 30,000 shares as secondary offering and upcoming earnings create a busy calendar for ALHC

By Priya Menon ALHC
Alignment Healthcare President Disposes $626K in Stock Amid Near-Term Catalysts
ALHC

Alignment Healthcare President Dawn Christine Maroney sold 30,000 shares on April 15, 2026, generating roughly $626,199 in proceeds. The sale was executed at prices between $20.76 and $21.07 per share. Maroney retains direct ownership of 1,028,813 shares. The transaction comes while the stock sits about 80% above its 52-week low and is noted by InvestingPro as trading below its Fair Value. Additional corporate developments include a 13.2 million share secondary offering by an affiliate of General Atlantic, L.P., and analyst reactions following robust fourth-quarter results.

Key Points

  • Dawn Christine Maroney sold 30,000 shares on April 15, 2026, for about $626,199 at $20.76 to $21.07 per share; she now directly owns 1,028,813 shares.
  • An affiliate of General Atlantic, L.P. is selling 13.2 million shares in a secondary offering priced at $19.46 per share; Alignment Healthcare will receive no proceeds and the offering is set to close on March 4, 2026, subject to customary conditions.
  • Analyst sentiment remains positive after strong fourth-quarter results - Raymond James reiterated a Strong Buy with a $27 target and Piper Sandler kept an Overweight rating with a $30 target - highlighting membership growth, revenue gains, medical benefit ratio, and adjusted EBITDA.

Alignment Healthcare (NASDAQ:ALHC) confirmed that its president, Dawn Christine Maroney, sold 30,000 shares of common stock on April 15, 2026, for approximately $626,199. The sales occurred at prices ranging from $20.76 to $21.07 per share, around the stock's current trading level of $20.92.

After completing the sale, Maroney's direct stake in Alignment Healthcare stands at 1,028,813 shares. The transaction was disclosed amid a market backdrop in which the company's shares are trading roughly 80% above their 52-week low. InvestingPro data cited alongside the transaction indicates the shares remain undervalued compared with their Fair Value.

Investors also have a near-term corporate event to monitor: earnings are scheduled in 14 days. The article notes analysts are forecasting that Alignment Healthcare will return to profitability this year. For market participants seeking deeper analysis, a comprehensive Pro Research Report is available for ALHC.


Separately, Alignment Healthcare announced a secondary offering by an affiliate of General Atlantic, L.P., consisting of 13.2 million shares priced at $19.46 per share. The company stated it will not receive any proceeds from this sale. That offering is scheduled to close on March 4, 2026, subject to customary closing conditions.

Market reactions following the company’s fourth-quarter results remain generally favorable among some sell-side analysts. Raymond James reiterated a Strong Buy rating and set a $27.00 price target after what the firm described as an impressive fourth quarter. Alignment Healthcare reported a 25% increase in membership and a 44.4% rise in revenue year-over-year for the fourth quarter, outpacing expectations.

Piper Sandler likewise kept an Overweight rating and established a $30.00 price target after the company’s fourth-quarter 2025 results exceeded expectations. Both firms highlighted metrics tied to the company’s performance, calling out the medical benefit ratio and adjusted EBITDA as notable contributors to their constructive stances.


The sequence of events - an insider sale, a large secondary offering by a private equity affiliate, and imminent earnings - places several items on investors' near-term watchlists. The reported analyst optimism on membership growth, revenue acceleration, and margin metrics provides context for why some firms retain favorable ratings despite the additional share supply announced by a third party.

Risks

  • The secondary offering of 13.2 million shares is subject to customary closing conditions, introducing uncertainty about the timing and finalization of that transaction - this affects capital markets activity for the company.
  • Earnings are scheduled in 14 days, representing an immediate near-term event that could change market perceptions or analyst forecasts.
  • Analyst expectations of profitability this year are projections and may be revised as new operational or financial data is released.

More from Insider Trading

Travere Legal Chief Sells $2.13M in Stock After Option Exercises and PSU Vesting Apr 15, 2026 Travere CFO Sells $348,974 in Stock Following PSU Vesting After FDA Approval Apr 15, 2026 Travere Commercial Chief Disposes $302,516 of Stock After Vesting Event and FDA Nod for Filspari Apr 15, 2026 Travere CEO Sells $2.63M in TVTX Shares as FILSPARI Gains FDA Approval Apr 15, 2026 Travere Therapeutics CMO Disposes $345k of TVTX Stock After PSU Vesting Apr 15, 2026